A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis
•IL-17A impairs the suppressive function of Tregs.•IL-17A limits the secretion of the inhibitory cytokine TGF-β in Tregs.•IL-17A phosphorylates NF-κB to promote the production of the inflammatory cytokine IFN-γ in Tregs.•Anti-IL-17A treatment with secukinumab in psoriasis restores the suppressive fu...
Saved in:
Published in | Journal of dermatological science Vol. 101; no. 2; pp. 84 - 92 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •IL-17A impairs the suppressive function of Tregs.•IL-17A limits the secretion of the inhibitory cytokine TGF-β in Tregs.•IL-17A phosphorylates NF-κB to promote the production of the inflammatory cytokine IFN-γ in Tregs.•Anti-IL-17A treatment with secukinumab in psoriasis restores the suppressive function of Tregs via the induction of TGF-β.
Regulatory T cells (Tregs) are crucial in maintaining T cell homeostasis and preventing autoimmune responses. Deficiencies in the suppressive function of Tregs contribute to the pathogenesis of various autoimmune diseases, such as psoriasis. However, whether IL-17A upregulation in psoriatic patients contributes to Treg dysfunction is unknown.
To explore the effect and underlying mechanism of IL-17A on the suppressive function of Tregs and to evaluate the restoration of the suppressive function of Tregs in psoriasis during anti-IL-17A (secukinumab) treatment.
In vitro suppression assays were performed with or without the addition of IL-17A to the coculture system. The release of inhibitory cytokines, including IL-10 and TGF-β, was assessed by qRT-PCR and flow cytometry. RNA-sequencing was conducted to characterize the cellular responses of Tregs. IL-17A signaling activation was analyzed by flow cytometry and immunofluorescence. Blood samples were collected from three psoriasis patients before and after secukinumab treatment.
IL-17A blocked the suppressive function of Tregs, possibly by inhibiting the release of TGF-β and promoting the production of IFN-γ. Moreover, IL-17A activated the NF-κB signaling pathway in Tregs. Inhibition of the NF-κB pathway blocked IL-17A-induced upregulation of IFN-γ without affecting the secretion of TGF-β by Tregs. Clinical treatment in psoriasis with secukinumab restored the suppressive function and increased production of TGF-β in Tregs of psoriasis.
Our study implies a crucial role of IL-17A in mediating the dysfunction of the Treg suppressive function in psoriasis. Secukinumab, which neutralizes IL-17A signaling, restored the suppressive function of Tregs to exert its antipsoriatic effect. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 0923-1811 1873-569X |
DOI: | 10.1016/j.jdermsci.2020.09.002 |